Market research
ARWR Arrowhead Pharmaceuticals Inc
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- 107.7143
- Dividend yield
- Not available
- Beta
- 1.3
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 8B
- P/E ratio
- Not available
- Analyst target
- 107.7143
- Dividend yield
- Not available
- Beta
- 1.3
About
About Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Research context
Arrowhead Pharmaceuticals Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the ARWR discussion.
5 years, 6 months ago
Arrowhead Pharmaceuticals, Inc is currently in a long term downtrend where the price is trading 9.3% below its 200 day moving average.
From a valuation standpoint, the stock is 93.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 86.0.
Arrowhead Pharmaceuticals, Inc's total revenue sank by 27.7% to $21M since the same quarter in the previous year.
Its net income has dropped by 675.4% to $-21M since the same quarter in the previous year.
Finally, its free cash flow fell by 55.1% to $-43M since the same quarter in the previous year.
Based on the above factors, Arrowhead Pharmaceuticals, Inc gets an overall score of 1/5.